Free Trial
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Citius Pharmaceuticals logo
$1.36 -0.01 (-0.44%)
As of 02:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Key Stats

Today's Range
$1.33
$1.39
50-Day Range
$0.91
$2.20
52-Week Range
$0.65
$15.25
Volume
98,914 shs
Average Volume
1.17 million shs
Market Capitalization
$23.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Consensus Rating
Moderate Buy

Company Overview

Citius Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

CTXR MarketRank™: 

Citius Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 394th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Citius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Citius Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($4.50) to $1.25 per share.

  • Price to Book Value per Share Ratio

    Citius Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.31% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Citius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Citius Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.31% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Citius Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    19 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.70% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 16.88% of the stock of Citius Pharmaceuticals is held by institutions.

  • Read more about Citius Pharmaceuticals' insider trading history.
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTXR Stock News Headlines

Citius Posts Wider Loss in Fiscal Q3
This strange black card is showing up across America
"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the White House just greenlit a $30 trillion upgrade to our financial system. Big firms like JP Morgan and Goldman Sachs are already onboard. And our Wall Street insider expects this change to create more wealth in the next 5 years than major innovations like the computer.tc pixel
See More Headlines

CTXR Stock Analysis - Frequently Asked Questions

Citius Pharmaceuticals' stock was trading at $4.00 at the start of the year. Since then, CTXR shares have decreased by 65.9% and is now trading at $1.3650.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04. The business earned $1.92 million during the quarter, compared to analysts' expectations of $1.92 million.

Shares of Citius Pharmaceuticals reverse split before market open on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Citius Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (0.72%), NewEdge Advisors LLC (0.24%), XTX Topco Ltd (0.19%) and Arkadios Wealth Advisors (0.19%).
View institutional ownership trends
.

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTXR
CIK
1506251
Fax
N/A
Employees
20
Year Founded
2007

Price Target and Rating

High Price Target
$100.00
Low Price Target
$6.00
Potential Upside/Downside
+3,768.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.14 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.03%
Return on Assets
-33.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
17,010,000
Free Float
15,192,000
Market Cap
$23.30 million
Optionable
Optionable
Beta
1.19

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CTXR) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners